Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P37837
UPID:
TALDO_HUMAN
Alternative names:
-
Alternative UPACC:
P37837; B2R8M2; O00751; Q8WV32; Q8WZ45
Background:
Transaldolase plays a pivotal role in the pentose phosphate pathway, catalyzing the conversion of sedheptulose-7-phosphate and D-glyceraldehyde 3-phosphate into erythrose-4-phosphate and beta-D-fructose 6-phosphate. This enzyme not only facilitates a key step in cellular metabolism but also influences other metabolic pathways through its dynamic localization between the nucleus and the cytoplasm.
Therapeutic significance:
Transaldolase deficiency, a rare genetic disorder, underscores the enzyme's critical function. Patients exhibit a spectrum of symptoms, including growth retardation and congenital heart disease, pointing to the enzyme's broad impact on health. Understanding the role of Transaldolase could open doors to potential therapeutic strategies for managing this multisystem disease.